Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 protein subunit recombinant vaccine
- Development stage
- Unknown
- Lead developer
- Bio Farma
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
SARS-CoV-2 protein subunit recombinant vaccine is a vaccine developed and manufactured by PT Bio Farma. It is designed to induce an immune response against the SARS-CoV-2 virus, the causative agent of COVID-19. The vaccine utilizes a recombinant protein subunit, specifically the Receptor Binding Domain (RBD) of the SARS-CoV-2 virus, to stimulate immunity and provide protection against infection.
- Other names
- 重组新冠病毒疫苗
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on SARS-CoV-2 protein subunit recombinant vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 protein subunit recombinant vaccine.